UPDATE: H.C. Wainwright Starts Ekso Bionics (EKSO) at Buy

---

News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.

---

(Updated - October 28, 2019 7:31 AM EDT)

(updated comment)

H.C. Wainwright analyst Swayampakula Ramakanth initiates coverage on Ekso Bionics (NASDAQ: EKSO) with a Buy rating and a price target of $1.20.

The analyst comments "Ekso Bionics develops and markets robotic exoskeletons for medical and industrial purposes. Its EksoHealth division markets Ekso GT, a device used for rehabilitation of patients who suffered a stroke or a spinal cord injury (SCI), and records 78% of Ekso revenues. The EksoWorks division markets robotics to improve endurance, strength, and safety of industrial workers. EksoHealth is the primary focus of management as they continue to refine their business strategy to ensure sustained growth. We project Ekso's total revenues to grow to $155M by 2030 from $15M in 2019, with 89% coming from EksoHealth."

For an analyst ratings summary and ratings history on Ekso Bionics click here. For more ratings news on Ekso Bionics click here.

Shares of Ekso Bionics closed at $0.59 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• UPDATE: BofA Securities Initiates Novavax (NVAX) at Underperform
• Vallourec SA (VK:FP) (VLOWY) PT Raised to EUR20 at Societe Generale
• UPDATE: Signify Health Inc (SGFY) PT Lowered to $20 at JPMorgan